Breadcrumbs

Blood and marrow transplant

Mobilisation

Protocol Administration at chemotherapy unit level Review date
Peripheral blood stem cell (PBSC) mobilisation protocol CYCLOPHOSPHamide High March 2020
Mobilisation of peripheral blood stem cells using plerixafor and G-CSF High March 2020

Autologous

(Patient treatment scheduling may differ between sites depending on local procedures).

Protocol Administration at chemotherapy unit level Review date
Autologous conditioning protocol busulfan and melphalan High September 2020
Autologous conditioning protocol primary CNS lymphoma carmustine and thiotepa High September 2020
Autologous conditioning protocol germ cell tumour TICE treatment overview High September 2020
Autologous conditioning protocol germ cell tumour TICE (PACLItaxel and IFOSFamide) (part 1) High September 2020
Autologous conditioning protocol germ cell tumour TICE (cARBOplatin and Etoposide) (part 2) High September 2020
Autologous conditioning protocol high dose melphalan 200 mg/m2 High September 2020
Autologous conditioning protocol BEAM (carmustine etoposide cytarabine melphalan) High September 2020
Autologous conditioning protocol high dose melphalan 140 mg/m2 High September 2020

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top